Dr. Alison Armour MB.,ChB., BSC., MSc., MD., FRCP., FRCR

Founder and CMO of Curadh

Why the future of molecularly targeted radiation needs At-211

ABSTRACT

Pluvicto brought the field of molecularly targeted radiation (MTR) into mainstream oncology and inspired massive investment in this space.

Curadh was formed to be a next generation MTR company and focus on new targets, in the most common, lethal tumors. This requires the development of specially designed molecules equipped with modern isotopes.

This presentation will summarize what we have learned from the clinical use of isotopes, key challenges to their clinical implementation in future and how At211 will be key to solving those challenges.

SPEAKER BIO

Alison practiced for many years in a major European oncology center. Trained in both medical and radiation oncology with a doctorate in 131I-mIBG therapy she had a large practice and was a major contributor to clinical trials. As a member of the EORTC lung group she was involved in many aspects of lung cancer research and was regarded as a key opinion leader in her field, before joining industry in 2014.

She has worked for AstraZeneca, GSK, Novartis, Endocyte and Halozyme. She is experienced in all stages of drug and diagnostic development and has a track record of multiple FDA and EMEA approvals for new treatments for cancer. Notably she developed the first molecularly targeted EGFR RTKi in lung cancer which drove the introduction of precision medicine in lung cancer.

Later in her career she clinically developed the first molecularly targeted radiation therapy for prostate cancer, PLUVICTO (PSMA617). She obtained the first regulatory approval of PSMA617 based on Phase 2 data. Pluvicto was acquired by NVS in 2019 for 2.1B$.
In 2021 she founded Curadh MTR, a biotech focused on the discovery of new molecularly targeted radiation therapies (MTR) against the most common lethal cancers. Curadh is developing molecules specifically designed for MTR. She also advises many company on their clinical radiopharmaceutical development.

She is married to Ian and has one daughter, who practices medicine in Cincinnati. Her hobbies are swimming, reading and portrait painting. She is a successful artist and has exhibited much of her work.

Return to conference agenda